STOCK TITAN

Genetic Technologies Ltd. - GENE STOCK NEWS

Welcome to our dedicated news page for Genetic Technologies Ltd. (Ticker: GENE), a resource for investors and traders seeking the latest updates and insights on Genetic Technologies Ltd..

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Genetic Technologies Ltd.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Genetic Technologies Ltd.'s position in the market.

Rhea-AI Summary
RedChip Companies will air interviews with Aridis Pharmaceuticals, Genetic Technologies Limited, and American Resources Corporation on The RedChip Money Report®, a sponsored program on Bloomberg TV.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.41%
Tags
none
-
Rhea-AI Summary
Genetic Technologies expands geneType Multi-Risk Test in Australia, offering assessments for Pancreatic Cancer, Melanoma, and Atrial Fibrillation
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Genetic Technologies Limited receives grant for CASSOWARY Trial to assess multi-cancer genetic risk assessment in general practice. Results expected to change risk assessment and improve care. GTG to receive funding for test kits and analysis. Trial to recruit 600 participants from eight general practices.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5%
Tags
none
Rhea-AI Summary
RedChip Companies will air interviews with Genetic Technologies Limited (GENE) and 60 Degrees Pharmaceuticals (SXTP) on The RedChip Money Report, a sponsored program on Bloomberg TV.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.25%
Tags
none
-
Rhea-AI Summary
Genetic Technologies reports annual results, with revenues of A$8.686 million, a +28% increase compared to 2022. Encouraging growth in geneType testing volumes. Development of Comprehensive Breast & Ovarian Cancer Risk Test. Strategic alliance with QIAGEN. Aim to attain profitability in the next 18 months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.37%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.95%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.22%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.08%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.08%
Tags
none
Genetic Technologies Ltd.

OTC:GENE

GENE Rankings

GENE Stock Data

13.21M
101.76M
0.64%
0.3%
Testing Laboratories
Professional, Scientific, and Technical Services
Link
Australia
Melbourne

About GENE

genetic technologies (asx: gtg, nasdaq global market: gene) is leading-edge genetic testing and reproductive services business which, together with an extensive range of international patents and allied research activities, aims at uncovering the impact of dna on health. throughout the asia pacific region, we translate specialised genetic tests into products and services that optimise the health knowledge and outcomes in humans, animals and plants.